secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tarsus Pharmaceuticals, Inc. (TARS)
CIK:        0001819790
Form:       8-K
Filed at:   2022-01-04T23:59:59+00:00
Accession:  0001819790-22-000002
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tarsus appoints Elizabeth Yeu, M.D. to Board of Directors
---------------------------------------------------------

- Dr. Yeu appointed as Class II director effective Dec 31, 2021; term expires at 2022 annual meeting.
- She continues as Chief Medical Advisor under consulting agreement with $240k annual cash compensation.
- Dr. Yeu brings over 20 years of eye care experience; will serve on Science and Technology Committee.
- Appointment comes as Tarsus nears potential commercialization of lead candidate TP-03 for Demodex blepharitis.
- No arrangements or understandings for her election; standard indemnification agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819790/000181979022000002/0001819790-22-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819790/000181979022000002/tars-20211231.htm
  HTML page:      https://secwatch.observer/filing/0001819790-22-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer